Meeting Unmet Needs for Patients With RCC
Martin H. Voss, MD, discusses the trajectory of the advanced renal cell carcinoma treatment landscape and provides clinical advice to community oncologists.
EP: 1.Overview of Advanced Non-Clear Cell Renal Cell Carcinoma
EP: 2.Current Treatment Options for Non-Clear Cell Renal Cell Carcinoma
EP: 3.IO-TKI Findings in nccRCC from KEYNOTE-B61
EP: 4.Duration of Therapy and Dosing Strategies in RCC
EP: 5.AE Management With IO-TKI and IO-IO in RCC
EP: 6.Multidisciplinary Strategies for Treating RCC
EP: 7.Meeting Unmet Needs for Patients With RCC
Video content above is prompted by the following question:
- What are the current unmet needs for patients with renal cell carcinoma (RCC)?
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Belzutifan Demonstrates Superior PFS, ORR vs Everolimus in Advanced RCC
August 23rd 2024LITESPARK-005 showed that belzutifan improved progression-free survival and objective response vs everolimus in patients with advanced clear cell renal cell carcinoma previously treated with immune checkpoint and antiangiogenic therapies.
Read More
Ornstein Discusses TKI Dose Interruption and Discontinuation in Combination RCC Therapy
August 19th 2024During a Case-Based Roundtable® event, Moshe Ornstein, MD, MA, discussed dose modification approaches for patients receiving combination immunotherapy/tyrosine kinase inhibitor therapy for advanced renal cell carcinoma.
Read More
